OncoSil Medical (ASX:OSL) received Medical Device Regulation certification from the European Union notified body BSI Group, according to a Tuesday filing with the Australian bourse.
The certification includes the lifting of existing post-market restrictions for the OncoSil cancer treatment device, simplifying the initiation of commercial treatments, the filing said.
The certification also offers the company a chance to re-submit its application to the Therapeutic Goods Administration for Australian market approval, according to the filing.
Oncosil shares surged 20% in recent trade Wednesday.
Price (AUD): $0.01, Change: $+0.0010, Percent Change: +20.00%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。